AKBA stock forecast Our latest prediction for Akebia Therapeutics, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$.. MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Researching Akebia Therapeutics (NASDAQ:AKBA) stock? View Akebia Therapeutics' earnings history. (Add your “outperform” vote. View our earnings forecast for Akebia Therapeutics. How Should You Play At Home Group (NYSE: HOME) Ahead of Earnings? Akebia Therapeutics's earnings in 2020 is -$390,940,000.On average, 4 Wall Street analysts forecast AKBA's earnings for 2020 to be $-256,179,865, with the lowest AKBA earnings forecast at $-266,570,377, and the highest AKBA earnings forecast at $-245,072,766. This suggests a possible upside of 210.7% from the stock's current price. Etsy (NASDAQ: ETSY) Shows No Signs Of Slowing After Record Black Friday, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240.2m in 2021, implying a stressful 22% … Akebia Therapeutics's revenue in 2020 is $308,163,000.On average, 4 Wall Street analysts forecast AKBA's revenue for 2020 to be $40,848,757,295, with the lowest AKBA revenue forecast at $40,584,623,314, and the highest AKBA revenue forecast at $41,188,132,915. Out of 6 analysts, 4 (66.67%) are recommending AKBA as a Strong Buy, 0 (0%) are recommending AKBA as a Buy, 2 (33.33%) are recommending AKBA as a Hold, 0 (0%) are recommending AKBA as a Sell, and 0 (0%) are recommending AKBA as a Strong Sell. Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). Akebia Therapeutics (AKBA) stock price prediction is 1.050727 USD. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. What is AKBA's forecast return on assets (ROA) for 2020-2023? The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. I saw some exciting stuff about Akebia Therapeutics for example I saw a few different stock forecasts giving it a forecast of $6 or even more (currently trades at $2.22). AKBA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Morgan Stanley, Squarepoint Ops LLC, Acadian Asset Management LLC, BlackRock Inc., SG Americas Securities LLC, AQR Capital Management LLC, and DekaBank Deutsche Girozentrale. AKBA Stock Analysis Overview . It's shaping up to be a tough period for Akebia Therapeutics, Inc. (NASDAQ:AKBA), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock.Statutory earnings fell substantially short of expectations, with revenues of US$60m missing forecasts by 33%. The firm has a Buy on the stock with an SELB stock forecast of $6. What is AKBA's revenue growth forecast for 2020-2022? To see all exchange delays and terms of use please see disclaimer. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Akebia Therapeutics has received 388 “outperform” votes. Akebia Therapeutics, Inc. (AKBA) estimates and forecasts Data shows that the Akebia Therapeutics, Inc. share is not performing relatively much better than most of its peers within the same industry. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Please note that any opinions, estimates or forecasts regarding Akebia Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Akebia Therapeutics or its management. The Akebia Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. According to 6 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $10.17, with the highest AKBA stock price forecast at $18.00 and the lowest AKBA stock price forecast at $3.00. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. 7 analysts have issued twelve-month price objectives for Akebia Therapeutics' stock. Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%.During that period the price should oscillate between -7.35% and +13.91%.. AKBA's Return on Equity is forecast to be high in 4 years (22.31%); analysts are confident in the firm's ability to efficiently generate return on equity, AKBA is forecast to generate higher Return on Assets (10.49%) than the US Biotechnology industry average (-0.4%), AKBA's revenue is forecast to grow at a rate of -10.35% per year, which is not exceptional, AKBA's revenues are forecast to grow slower (-10.35% per year) than the US Biotechnology industry average (44.39%), AKBA's revenues are forecast to grow slower (-10.35% per year) than the US market average (5.86%). Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year The analysts covering Akebia Therapeutics, Inc. … Hi everyone! Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. Akebia Therapeutics does not currently pay a dividend. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.25. AKBA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nantahala Capital Management LLC, Charles Schwab Investment Management Inc., Cubist Systematic Strategies LLC, Sei Investments Co., Skandinaviska Enskilda Banken AB publ , Quantitative Systematic Strategies LLC, and Massachusetts Financial Services Co. MA. Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2020-09 … Based on 8 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. AKEBIA THERAPEUTICS INC stock price forecast for further price development up to 240.68% (time horizon: 1 day) and price target of 9.27 USD. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. What is AKBA's Earnings Per Share (EPS) forecast for 2020-2022? The consensus among 6 Wall Street analysts covering (NASDAQ: AKBA) stock is to Strong Buy AKBA stock. During the day the stock fluctuated 10.87% from a day low at $2.30 to a day high of $2.55. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts … Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. High institutional ownership can be a signal of strong market trust in this company. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. ), Akebia Therapeutics has received 329 “underperform” votes. Akebia Therapeutics has a market capitalization of $478.42 million and generates $335 million in revenue each year. Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021. Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA.". Akebia reported that patients who took Vadadustat were shown to have increased heart risks, especially when compared to a similar treatment made by rival Amgen (NASDAQ:AMGN). View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. One share of AKBA stock can currently be purchased for approximately $3.31. Penny Stocks To Buy [according to HC Wainwright]: Akebia Therapeutics Inc. Akebia Therapeutics has received 54.11% “outperform” votes from our community. (Add your “underperform” vote.). Please log in to your account or sign up in order to add this asset to your watchlist. Since then, AKBA stock has decreased by 52.3% and is now trading at $3.31. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Great Point Partners LLC acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at $47,667,000. Akebia Therapeutics, Inc. Stock Price Forecast, "AKBA" Predictons for2020 As can be gleaned from the statistics, the company’s share value dive -76.3% over the past 6 months, a 11.44% in annual growth rate that is considerably lower than the industry average of 15.4%. In 2022, AKBA is forecast to generate $31,819,187,385 in revenue, with the lowest revenue forecast at $27,194,477,978 and the highest revenue forecast at $38,146,220,952. AKBA stock … On average, 4 Wall Street analysts forecast AKBA's revenue for 2021 to be $35,937,699,710, with the lowest AKBA revenue forecast at $24,430,745,102, and the highest AKBA revenue forecast at $61,336,983,848. Akebia Therapeutics Inc (AKBA:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Fundamental company data provided by Morningstar and Zacks Investment Research. Akebia Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. 76.15% of the stock of Akebia Therapeutics is held by institutions. View analyst ratings for Akebia Therapeutics or view MarketBeat's top 5 stock picks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Analysts have given the company’s stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10. Learn more. AKBA Stock Analysis Overview . Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. All rights reserved. Wondering if anyone in the reddit community has something to say about it? Akebia Therapeutics' management team includes the following people: Start Your Risk-Free Trial Subscription Here, Moderna (NASDAQ:MRNA) Makes Explosive Gains in Pre-Market, The Top Two Sectors For The Q4 Earnings Season. The Michaels Companies (NYSE: MIK) Stock is a Dual Narrative Play, Organigram (NASDAQ:OGI) Rockets Higher After Q4 Earnings, FuelCell (NASDAQ: FCL) Stock is an Alternative Energy Pullback Buy at These Levels. Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. (NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of -10.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.86%. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. The Akebia Therapeutics stock forecast is 1.050727 USD for 2021 November 14, Sunday; and 4.637 USD for 2025 November 14, Friday with technical analysis. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next year. Akebia Therapeutics has a P/B Ratio of 1.50. Akebia Therapeutics does not have a long track record of dividend growth. View our full suite of financial calendars and market data tables, all for free. The P/E ratio of Akebia Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. See what's happening in the market right now with MarketBeat's real-time news feed. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. View institutional ownership trends for Akebia Therapeutics. What is AKBA's forecast return on equity (ROE) for 2020-2023? Their forecasts range from $3.00 to $18.00. Looking for new stock ideas? Want to see which stocks are moving? Learn more. Is Akebia Therapeutics Stock a good buy in 2020, according to Wall Street analysts? Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.79) to ($0.73) per share. According to analysts' consensus price target of $10.29, Akebia Therapeutics has a forecasted upside of 210.7% from its current price of $3.31. On average, 4 Wall Street analysts forecast AKBA's earnings for 2021 to be $-104,621,707, with the lowest AKBA earnings forecast at $-225,008,329, and the highest AKBA earnings forecast at $67,359,181. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings. ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug Receive a free world-class investing education from MarketBeat. Top institutional shareholders include State Street Corp (10.70%), BlackRock Inc. (8.19%), Nantahala Capital Management LLC (3.98%), Morgan Stanley (0.83%), Squarepoint Ops LLC (0.71%) and Charles Schwab Investment Management Inc. (0.65%). View which stocks are hot on social media with MarketBeat's trending stocks report. Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Find the latest Earnings Report Date for Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. View which stocks have been most impacted by COVID-19. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Get short term trading ideas from the MarketBeat Idea Engine. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information. Identify stocks that meet your criteria using seven unique stock screeners. Akebia Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Shares of AKBA can be purchased through any online brokerage account. Learn everything you need to know about successful options trading with this three-part video course. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Analysts forecast that Akebia Therapeutics will post -1.5 earnings per share for the current year. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. View analysts' price targets for Akebia Therapeutics. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Akebia Therapeutics is followed by the analysts listed above. Thanks a million! View insider buying and selling activity for Akebia Therapeutics. Vote “Outperform” if you believe AKBA will outperform the S&P 500 over the long term. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Hedge funds have recently modified their holdings of the company. Export data to Excel for your own analysis. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials The official website for Akebia Therapeutics is www.akebia.com. © American Consumer News, LLC dba MarketBeat® 2010-2020. This is 3.11% less than the trading day before Wednesday, 4th Nov 2020. You may vote once every thirty days. (NASDAQ: AKBA) Akebia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of -1.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 12.63%. What this means: InvestorsObserver gives Akebia Therapeutics Inc (AKBA) an overall rank of 34, which is below average. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock. Its products include Auryxia and Vadadustat. Akebia Therapeutics had a negative net margin of 126.86% and a negative return on equity of 68.51%. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The average price target is $6.71 with a high forecast of $10.00 and a low forecast of $3.00.The average price target represents a 103.33% increase from the last price of $3.30. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Maxine Gowen, Michel Dahan, and Nicole R Hadas. What is AKBA's earnings growth forecast for 2020-2022? It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. Akebia Therapeutics Inc (AX9:MUN) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. In comparing Akebia Therapeutics, Inc. (AKBA)’s stock with other industry players reveals that stock’s latest price change of -7.96% and that of -22.65% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price raised by 0.93% in the recent trading and went through an increase of 31.24% in past 12-month trading. Despite being -2.12% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 19 when the AKBA stock price touched $3.96-6 or saw a rise of 6.57%.
2020 akebia therapeutics stock forecast